Psychedelic Drugs Global Market Report 2026

Description

Psychedelic drugs are a class of psychoactive substances that alter perception, mood, and thought processes. They affect all the senses, influencing a person's thinking, sense of time, and emotions. This category includes synthetic compounds such as lysergic acid diethylamide (LSD) as well as naturally occurring substances like peyote, and these drugs are used to treat various brain-related conditions.

The main types of psychedelic drugs include lysergic acid diethylamide (LSD), ketamine, phencyclidine, gamma-hydroxybutyric acid (GHB), and salvia. LSD, also known as acid, is produced in crystalline form and then combined with inert ingredients or diluted as a liquid for ingestion. Psychedelic drugs are indicated for conditions such as depression and PTSD, whether naturally occurring or synthetic. Their applications include treatment-resistant depression, opiate addiction, post-traumatic stress disorder, narcolepsy, and panic disorders. These drugs are distributed through hospital pharmacies, retail pharmacies, and online platforms.

Tariffs have moderately impacted the psychedelic drugs market by increasing the cost of importing active pharmaceutical ingredients, laboratory equipment, and specialized manufacturing inputs used in synthetic psychedelic production. these effects are most pronounced across synthetic drug segments such as lsd and ketamine and in regions reliant on cross-border pharmaceutical supply chains, particularly north america and europe. however, tariffs are also encouraging localized manufacturing, domestic api sourcing, and investment in regional production capabilities, which may strengthen long-term supply resilience and reduce dependency on imports.

The psychedelic drugs market research report is one of a series of new reports from The Business Research Company that provides psychedelic drugs market statistics, including psychedelic drugs industry global market size, regional shares, competitors with a psychedelic drugs market share, detailed psychedelic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the psychedelic drugs industry. This psychedelic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The psychedelic drugs market size has grown rapidly in recent years. It will grow from $6.33 billion in 2025 to $7.37 billion in 2026 at a compound annual growth rate (CAGR) of 16.4%. The growth in the historic period can be attributed to high unmet need in depression treatment, early academic research on psychedelics, underground and compassionate use cases, limited efficacy of conventional antidepressants, rising mental health awareness.

The psychedelic drugs market size is expected to see rapid growth in the next few years. It will grow to $13.67 billion in 2030 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to regulatory approvals for medical use, growing psychiatrist adoption, expansion of indication pipeline, improved patient outcomes data, strategic partnerships between biotech and healthcare providers. Major trends in the forecast period include expansion of psychedelic-assisted therapy programs, increasing clinical trials for mental health indications, growing acceptance of alternative psychiatry treatments, regulatory pathway clarification for controlled substances, rising investment from venture capital and pharma players.

The rising prevalence of mental illnesses is expected to drive the growth of the psychedelic drugs market. Mental illnesses are health conditions that affect emotions, thinking, or behavior, including disorders such as depression and post-traumatic stress disorder (PTSD). Psychedelic drugs are increasingly being used to treat these conditions, helping to alleviate symptoms and improve patient outcomes. For instance, in November 2023, according to the National Health Service, a UK-based government agency, approximately one in five individuals aged 8 to 25 years was estimated to have a probable mental disorder, impacting 20.3% of 8-16-year-olds, 23.3% of 17-19-year-olds, and 21.7% of 20-25-year-olds. Therefore, the growing incidence of mental health disorders is driving demand for psychedelic therapeutics.

Major companies in the psychedelic drugs market are focusing on developing pharmaceutical-grade psilocybin formulations to enhance therapeutic efficacy, ensure safety, and expand treatment options. Pharmaceutical-grade psilocybin refers to psilocybin produced under strict quality standards, ensuring consistent potency, purity, and safety for clinical use. For example, in September 2025, Optimi Health, an Australia-based psychedelic therapeutics company, launched its natural psilocybin capsules in Australia for the treatment of treatment-resistant depression (TRD). This launch aims to provide a clinically supported treatment option, strengthen Optimi Health's presence in the Australian mental health market, and accelerate the adoption of psychedelic-assisted therapies.

In October 2023, Cybin Inc., a Canada-based psychedelic therapeutics company, completed the acquisition of Small Pharma Inc., a UK-based clinical-stage biotechnology company focused on psychedelic therapies, for an undisclosed amount. This acquisition positions Cybin as an international clinical-stage leader in novel psychedelic therapeutics, expands its pipeline of psilocybin-based treatments, accelerates clinical development, and strengthens its research and commercialization capabilities.

Major companies operating in the psychedelic drugs market are Atai Life Sciences, Cybin Inc., Mind Medicine Inc., Compass Pathways, Seelos Therapeutics, Numinus Wellness Inc., GH Research, Revive Therapeutics, Havn Life Sciences, PharmaTher Holdings, Field Trip Health, Small Pharma, Incannex Healthcare, Optimi Health, NeonMind Biosciences, Entheon Biomedical, Mydecine Innovations Group, Red Light Holland, Eleusis, MAPS Public Benefit Corporation, Beckley Psytech, Awakn Life Sciences, Psygen Industries, Enveric Biosciences, Filament Health, Tactogen, Bexson Biomedical, BetterLife Pharma, Clairvoyant Therapeutics, Universal Ibogaine

North America was the largest region in the psychedelic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psychedelic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the psychedelic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The psychedelic drugs market consists of sales of psilocybin, PCP, cannabis, and ecstasy. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Psychedelic Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses psychedelic drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for psychedelic drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The psychedelic drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Type: Lysergic Acid Diethylamide (LSD); Ketamine; Phencyclidine; Gamma Hydroxybutyric Acid (GHB); Salvia
2) By Disease Indication: Depression; PTSD
3) By Origin: Natural; Synthetic
4) By Application: Treatment-Resistant Depression; Opiate addiction; Post- Traumatic Stress Disorder; Narcolepsy; Panic Disorders
5) By Distribution Channel: Hospitals Pharmacy; Retail Pharmacy; Online Pharmacy
Subsegments:
1) By Lysergic Acid Diethylamide (LSD): LSD Tablets; LSD Liquid; LSD Blotters
2) By Ketamine: Ketamine Infusion; Ketamine Nasal Spray; Ketamine Injectable
3) By Phencyclidine (PCP): PCP Powder; PCP Tablets; PCP Liquid
4) By Gamma Hydroxybutyric Acid (GHB): GHB Liquid; GHB Powder; GHB Capsules
5) By Salvia: Salvia Extract; Salvia Dried Leaves; Salvia Tinctures
Companies Mentioned: Atai Life Sciences; Cybin Inc.; Mind Medicine Inc.; Compass Pathways; Seelos Therapeutics; Numinus Wellness Inc.; GH Research; Revive Therapeutics; Havn Life Sciences; PharmaTher Holdings; Field Trip Health; Small Pharma; Incannex Healthcare; Optimi Health; NeonMind Biosciences; Entheon Biomedical; Mydecine Innovations Group; Red Light Holland; Eleusis; MAPS Public Benefit Corporation; Beckley Psytech; Awakn Life Sciences; Psygen Industries; Enveric Biosciences; Filament Health; Tactogen; Bexson Biomedical; BetterLife Pharma; Clairvoyant Therapeutics; Universal Ibogaine
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH4MPDRU02_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Psychedelic Drugs Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Psychedelic Drugs Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Psychedelic Drugs Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Psychedelic Drugs Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Artificial Intelligence & Autonomous Intelligence
- 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.4 Sustainability, Climate Tech & Circular Economy
- 4.1.5 Healthcare Innovation & Advanced Therapeutics
4.2. Major Trends
- 4.2.1 Expansion Of Psychedelic-Assisted Therapy Programs
- 4.2.2 Increasing Clinical Trials For Mental Health Indications
- 4.2.3 Growing Acceptance Of Alternative Psychiatry Treatments
- 4.2.4 Regulatory Pathway Clarification For Controlled Substances
- 4.2.5 Rising Investment From Venture Capital And Pharma Players

5. Psychedelic Drugs Market Analysis Of End Use Industries

5.1 Hospitals And Specialty Clinics
5.2 Psychiatric Treatment Centers
5.3 Rehabilitation And Addiction Treatment Centers
5.4 Research And Academic Institutes
5.5 Mental Health Specialty Clinics

6. Psychedelic Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Psychedelic Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Psychedelic Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Psychedelic Drugs Market Size, Comparisons And Growth Rate Analysis
7.3. Global Psychedelic Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Psychedelic Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Psychedelic Drugs Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Psychedelic Drugs Market Segmentation

9.1. Global Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Lysergic Acid Diethylamide (LSD), Ketamine, Phencyclidine, Gamma Hydroxybutyric Acid (GHB), Salvia
9.2. Global Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Depression, PTSD
9.3. Global Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Natural, Synthetic
9.4. Global Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Treatment-Resistant Depression, Opiate addiction, Post- Traumatic Stress Disorder, Narcolepsy, Panic Disorders
9.5. Global Psychedelic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy
9.6. Global Psychedelic Drugs Market, Sub-Segmentation Of Lysergic Acid Diethylamide (LSD), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
LSD Tablets, LSD Liquid, LSD Blotters
9.7. Global Psychedelic Drugs Market, Sub-Segmentation Of Ketamine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Ketamine Infusion, Ketamine Nasal Spray, Ketamine Injectable
9.8. Global Psychedelic Drugs Market, Sub-Segmentation Of Phencyclidine (PCP), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
PCP Powder, PCP Tablets, PCP Liquid
9.9. Global Psychedelic Drugs Market, Sub-Segmentation Of Gamma Hydroxybutyric Acid (GHB), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
GHB Liquid, GHB Powder, GHB Capsules
9.10. Global Psychedelic Drugs Market, Sub-Segmentation Of Salvia, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Salvia Extract, Salvia Dried Leaves, Salvia Tinctures

10. Psychedelic Drugs Market Regional And Country Analysis

10.1. Global Psychedelic Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Psychedelic Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Psychedelic Drugs Market

11.1. Asia-Pacific Psychedelic Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Psychedelic Drugs Market

12.1. China Psychedelic Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Psychedelic Drugs Market

13.1. India Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Psychedelic Drugs Market

14.1. Japan Psychedelic Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Psychedelic Drugs Market

15.1. Australia Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Psychedelic Drugs Market

16.1. Indonesia Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Psychedelic Drugs Market

17.1. South Korea Psychedelic Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Psychedelic Drugs Market

18.1. Taiwan Psychedelic Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Psychedelic Drugs Market

19.1. South East Asia Psychedelic Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Psychedelic Drugs Market

20.1. Western Europe Psychedelic Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Psychedelic Drugs Market

21.1. UK Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Psychedelic Drugs Market

22.1. Germany Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Psychedelic Drugs Market

23.1. France Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Psychedelic Drugs Market

24.1. Italy Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Psychedelic Drugs Market

25.1. Spain Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Psychedelic Drugs Market

26.1. Eastern Europe Psychedelic Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Psychedelic Drugs Market

27.1. Russia Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Psychedelic Drugs Market

28.1. North America Psychedelic Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Psychedelic Drugs Market

29.1. USA Psychedelic Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Psychedelic Drugs Market

30.1. Canada Psychedelic Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Psychedelic Drugs Market

31.1. South America Psychedelic Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Psychedelic Drugs Market

32.1. Brazil Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Psychedelic Drugs Market

33.1. Middle East Psychedelic Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Psychedelic Drugs Market

34.1. Africa Psychedelic Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Psychedelic Drugs Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Origin, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Psychedelic Drugs Market Regulatory and Investment Landscape

36. Psychedelic Drugs Market Competitive Landscape And Company Profiles

36.1. Psychedelic Drugs Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Psychedelic Drugs Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Psychedelic Drugs Market Company Profiles
- 36.3.1. Atai Life Sciences Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Cybin Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Mind Medicine Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Compass Pathways Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Seelos Therapeutics Overview, Products and Services, Strategy and Financial Analysis

37. Psychedelic Drugs Market Other Major And Innovative Companies

Numinus Wellness Inc., GH Research, Revive Therapeutics, Havn Life Sciences, PharmaTher Holdings, Field Trip Health, Small Pharma, Incannex Healthcare, Optimi Health, NeonMind Biosciences, Entheon Biomedical, Mydecine Innovations Group, Red Light Holland, Eleusis, MAPS Public Benefit Corporation

38. Global Psychedelic Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Psychedelic Drugs Market

40. Psychedelic Drugs Market High Potential Countries, Segments and Strategies

40.1 Psychedelic Drugs Market In 2030 - Countries Offering Most New Opportunities
40.2 Psychedelic Drugs Market In 2030 - Segments Offering Most New Opportunities
40.3 Psychedelic Drugs Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations
41.2. Currencies
41.3. Historic And Forecast Inflation Rates
41.4. Research Inquiries
41.5. The Business Research Company
41.6. Copyright And Disclaimer